» Articles » PMID: 29180222

Intranasal Insulin in Alzheimer's Disease: Food for Thought

Overview
Specialties Neurology
Pharmacology
Date 2017 Nov 29
PMID 29180222
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulating evidence suggests that disrupted brain insulin signaling promotes the development and progression of Alzheimer's disease (AD), driving clinicians to target this circuitry. While both traditional and more modern antidiabetics show promise in combating insulin resistance, intranasal insulin appears to be the most efficient method of boosting brain insulin. Furthermore, intranasal delivery elegantly avoids adverse effects from peripheral insulin administration. However, there remain significant open questions regarding intranasal insulin's efficacy, safety, and potential as an adjunct or mono-therapy. Thus, this review aims to critically evaluate the present evidence and future potential of intranasal insulin as a meaningful treatment for AD. This article is part of the Special Issue entitled 'Metabolic Impairment as Risk Factors for Neurodegenerative Disorders.'

Citing Articles

Insulin resistance in Alzheimer's disease: signalling mechanisms and therapeutics strategies.

Dahiya M, Yadav M, Goyal C, Kumar A Inflammopharmacology. 2025; .

PMID: 40064805 DOI: 10.1007/s10787-025-01704-2.


Nose to brain strategy coupled to nano vesicular system for natural products delivery: Focus on synaptic plasticity in Alzheimer's disease.

Maisto N, Mango D J Pharm Anal. 2025; 14(12):101057.

PMID: 39802402 PMC: 11718335. DOI: 10.1016/j.jpha.2024.101057.


Mechanism of traditional Chinese medicine in elderly diabetes mellitus and a systematic review of its clinical application.

Zhang Q, Hu S, Jin Z, Wang S, Zhang B, Zhao L Front Pharmacol. 2024; 15:1339148.

PMID: 38510656 PMC: 10953506. DOI: 10.3389/fphar.2024.1339148.


Distribution of insulin in primate brain following nose-to-brain transport.

Smith K, Fan J, Marriner G, Gerdes J, Kessler R, Zinn K Alzheimers Dement (N Y). 2024; 10(1):e12459.

PMID: 38469552 PMC: 10925727. DOI: 10.1002/trc2.12459.


Synthesis of a Rivastigmine and Insulin Combinational Mucoadhesive Nanoparticle for Intranasal Delivery.

Jamshidnejad-Tosaramandani T, Kashanian S, Karimi I, Schioth H Polymers (Basel). 2024; 16(4).

PMID: 38399888 PMC: 10891873. DOI: 10.3390/polym16040510.


References
1.
Benedict C, Dodt C, Hallschmid M, Lepiorz M, Fehm H, Born J . Immediate but not long-term intranasal administration of insulin raises blood pressure in human beings. Metabolism. 2005; 54(10):1356-61. DOI: 10.1016/j.metabol.2005.04.026. View

2.
Rosenbloom M, Barclay T, Pyle M, Owens B, Cagan A, Anderson C . A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. CNS Drugs. 2014; 28(12):1185-9. DOI: 10.1007/s40263-014-0214-y. View

3.
Mamik M, Asahchop E, Chan W, Zhu Y, Branton W, McKenzie B . Insulin Treatment Prevents Neuroinflammation and Neuronal Injury with Restored Neurobehavioral Function in Models of HIV/AIDS Neurodegeneration. J Neurosci. 2016; 36(41):10683-10695. PMC: 6601935. DOI: 10.1523/JNEUROSCI.1287-16.2016. View

4.
Jauch-Chara K, Friedrich A, Rezmer M, Melchert U, Scholand-Engler H, Hallschmid M . Intranasal insulin suppresses food intake via enhancement of brain energy levels in humans. Diabetes. 2012; 61(9):2261-8. PMC: 3425399. DOI: 10.2337/db12-0025. View

5.
Thorne R, Emory C, Ala T, Frey 2nd W . Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res. 1995; 692(1-2):278-82. DOI: 10.1016/0006-8993(95)00637-6. View